A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) (CHAMPION)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01156571|
Recruitment Status : Completed
First Posted : July 5, 2010
Results First Posted : June 18, 2013
Last Update Posted : February 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Atherosclerosis Percutaneous Coronary Intervention Acute Coronary Syndrome||Drug: cangrelor P2Y12 (platelet) inhibitor Drug: Clopidogrel - 300 or 600 mg (study arm) Drug: Clopidogrel 600 mg post cangrelor||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11145 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered.
Drug: cangrelor P2Y12 (platelet) inhibitor
Drug: Clopidogrel 600 mg post cangrelor
over-encapsulated clopidogrel (600 mg)
Active Comparator: clopidogrel
Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.
During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm.
Drug: Clopidogrel - 300 or 600 mg (study arm)
Over encapsulated tablets.
- The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST) [ Time Frame: 48 hours after randomization ]Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population)
- Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR) [ Time Frame: 48 hours after randomization ]CEC-adjudicated results (mITT population)
- Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild [ Time Frame: 48 hours after randomization ]GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01156571
|United States, South Carolina|
|Anderson Area Medical Center|
|Anderson, South Carolina, United States, 29621|